France Pharmaceuticals Market Size, Share & Trends Analysis Report By Molecule Type, By Product, By Type, By Disease, By Formulation, By Age Group, By Route Of Administration, By End Market, And Segment Forecasts, 2024 - 2030

France Pharmaceuticals Market Trends  

The France pharmaceuticals market size was estimated at USD 78.78 billion in 2023 and is expected to grow at a compound annual growth rate (CAGR) of 5.16% from 2024 to 2030. France is considered as one of the largest pharmaceutical markets owing to high R&D activities, and transparent regulatory support by government bodies and steady efforts by government entities to improve and expand access to healthcare to consumers. For instance, in August 2023, French government presented its plan to reshore the production of essential medicines to ensure that patients receive access to all the products including established & mature medicines as well as innovative medicines.

France is the most regulated market and hence is growing continuously since the last decade and over the forecast period as well. In addition, the lucrative industrial, scientific drug research and local presence of key leaders in the country significantly impact the growth of the market. The government personnel focus on country’s scientific research and innovation and also take initiatives to make it forefront in the European healthcare domain. For instance, in June 2023, President Emmanuel Macron of France came up with an innovation plan for France. This plan will eventually strengthen biomedical research capabilities in the country and support the country to sustain its position with a higher rank in the European healthcare sector.

Moreover, France has robust potential for infrastructure building, new expansion opportunities, and new drug development. Furthermore, increasing R&D investments, manufacturing of emerging biosimilar and biologics, and supportive reimbursement framework and regulatory policies will significantly increase the adoption of pharmaceutical demand in the country, leveraging the market.

The market is further positively influenced by key factors such as growing consumption of generic drugs, beneficial tax incentives, geriatric population, high healthcare expenditure, and the presence of skilled personnel. As per the report published by Le Monde in March 2023, around 26 % of the population of France consists of people more than 60 years of age, and the percentage is likely to increase by 2040.

Market Concentration & Characteristics

Degree of Innovation: The introduction of new products diversifies the consumer’s preferences and market trends, eventually exceeding the demand in the market. Several key companies are actively participating in innovation and making efforts to invest in R&D sections. For instance, In March 2022, Huma Therapeutics Limited announced a collaboration with AstraZeneca to step into an innovative space to advance digital first-care delivery and research. This partnership will improve clinical outcomes between patients and clinicians using digital platforms.

Level of M&A Activities: The growth of the market in France is highly supported by merger and acquisition activities undertaken by pharmaceutical companies. These activities not only help in expanding the company’s portfolio but also increase its share in the market. For instance, in October 2023, Cooper Consumer Health announced the acquisition of Viatris Inc. for Overt-the-Counter business. This acquisition will help Cooper Consumer Health to sustain its position as a prominent player in European healthcare.

Several key market players focus on regional expansion to establish a high range of customers and leverage market growth geographically. For instance, in November 2023, Novo Nordisk announced its investment of 2.1 billion euros in a manufacturing plant in France. This agreement aims to expand the production capacity for anti-obesity drugs, thereby increasing its demand in the market.

The regulatory agencies such as the National Agency for the Safety of Medicinal and Health Products regulate pharmaceutical products and device approvals in the country. The regulations are very rigid and stringent, which restraining the demand in the market.

Age Group Insights

The adult segment held the largest share of 53.25% in the pharmaceuticals market in 2023 and is further expected to advance at the fastest growth rate over the forecast period. The higher prevalence of geriatric as well as adult population is likely to increase the demand for prescription medicines. As per LeMonde, around 26% of the people are over the age of 60 in France . The most commonly used drugs among the adult population include NSAIDs, lipid-lowering drugs, ACE inhibitors, analgesics, and antidepressants.

The children & adolescent segment is expected to witness strong growth from 2024 to 2030. This growth is likely due to the rising number of medication approvals for the pediatric population. For instance, in June 2023, Pfizer Inc., in collaboration with OPKO Health Inc., received FDA approval for NGENLA, a human growth hormone medication used to treat pediatric patients. It is expected to be available for prescription in August 2023. A rising prevalence of various disorders in this population, including respiratory conditions, infectious diseases, and rare conditions, is further anticipated to fuel segment growth.

Molecule Type Insights

Based on molecule type, the market for conventional drugs (small molecules) dominated the market with a revenue share of 55.16 % in 2023. The driving factors accelerating market growth include structured manufacturing facilities, predictable pharmacokinetics, and oral bioavailability. As per the Public Health European Commission report, cancer is the prominent cause of death in France. Conventional drugs are a relevant therapeutic option for cancer treatment thereby enabling manufacturers to contribute to their R&D innovation and consumer adoption.  These parameters will likely enhance market growth in the forecast period.

The biologics& biosimilar segment is expected to witness growth with the fastest CAGR from 2024 to 2030. This will likely expand due to steady demand, its significance, and the therapeutic advances of the molecules. Moreover, several key companies are investing in biologics to get more consumer engagement and expand their geographical expansion. For instance, in September 2022, Evotec SE announced establishment of manufacturing facility in Evotec’s Campus at J.POD Toulouse, France. This initiative employed clinical an dcommercial capacity for biologics.

Product Insights

The branded segment dominated the pharmaceutical market with a revenue share of 69.15% in 2023. The growth of the segment is attributed to the rising prevalence of chronic diseases, increasing R&D and approval of novel pharmaceuticals, and the rising demand for innovative therapies to treat various conditions. Major players operating in the market are constantly focusing on introducing novel pharmaceuticals, further propelling segment growth. In December 2023, the US FDA approved two gene therapies namely Lyfgenia Lyfgenia from Bluebird Bio and Casgevy by partners Vertex Pharmaceuticals and CRISPR therapeutics for sickle cell anemia(SCA). This innovative treatment is based on Crispr-gene editing technology. This promising therapy will deliver the targeted and effective treatment for patients suffering through SCA.

The generic segment's growth is attributed to an increasing number of ANDA approvals and generic drug launches. Furthermore, the COVID-19 pandemic has led to a surge in demand for antibiotics and other medications. Several key players aim to focus on the development of generics to increase earnings and expand their market position. In 2022, Dr. Reddy’s Laboratories launched its generic lenalidomide capsules in the U.S. to enhance its product expansion geographically.

Type Insights

The prescription segment held a dominant revenue share of 81.52% in 2022 of the France pharmaceutical market. The dominance is owing to the increasing R&D investments by major players in the market for developing novel pharmaceuticals, which are majorly used in the treatment of chronic diseases. With the rising prevalence of such disorders, there has been an increase in patient demand due to unmet clinical needs and a desire for favorable therapeutic outcomes.

Consequently, prominent companies in the French pharmaceutical market are actively engaged in clinical trials to develop and ultimately gain approval for new products. Additionally, the growing rate of hospitalizations and prescriptions is further fueling the overall growth of the pharmaceutical market.

The OTC segment is expected to witness the fastest growth from 2024 to 2030. This growth can be attributed to local presence of OTC manufacturing comapnaies. The companies include Boiron, Sanofi, and Pierre Fabre. To expand consumers and sales, key companies undertake some M&A activities.

Disease Insights

Based on disease,the cancer segment dominated the overall market with a share of 13.85 % in 2023. The dominance of this segment in the France pharmaceutical market is attributed to several key factors such as the rising prevalence of cancer and increasing innovation in cancer therapeutics. Also, advancements in personalized medicine & targeted therapies have revolutionized cancer treatment, offering higher efficacy and fewer side effects. As per the European Cancer Information System, 31 % of men and 25 % of women in the European region For instance, in September 2023,  Roche France announced collaboration with Institute Gustave Roussy to offer in-house liquid biopsy genomic testing to treat cancer patients. This liquid biopsy testing will further help cancer patients when tissue biopsy is not available.

Furthermore, the infectitous diseases segment is expected to witness growth with the fastest CAGR from 2024 to 2030. The prevalence of infectitous diseases in France leveraging this growth. Also, healthcare agencies are implementing startergic initiatives  to enhance prevention and treatment of infectitous diseases in the country. For instance, WHO announced new National Strategy for Preventing Infections and Antibiotic Resistsance with partnership with National and regional helath authorities of France.

Route of Administration Insights

Based on the route of administration, the oral route dominated the market with a revenue share of 57.9 % in 2023. The factors driving the growth of the market include several key factors such as ease of use, quick absorption into the bloodstream, and high patient compliance due to their non-invasive nature, resulting in increased adherence rates.

The parenteral route of administration is expected to expand at the fastest CAGR over the forecast period. Recent advancements in parenteral drug delivery have transformed the French pharmaceutical Market landscape. For instance, in march 2023, CARBOGEN AMCIS announced the launch of new manufacturing facility for parenteral drug products. This new facility will provide larger facility for phase IIl Clinical trials and small scale commercial manufacturing.

Formulation Insights

Tablets held the largest market share of 22.73% in 2023 of the pharmaceuticals market. The diverse use of tablets in oral solid dosage form contributes to their enormous manufacturing and sales. This formulation is adopted at a higher rate owing to tamper resistance, cost-effectiveness, ease of handling and packing, and high manufacturing efficiency. Tablets are the simplest to produce for a wide range of specializations, including anti-diabetics, anti-inflammatories, antacids, vitamins, and antiallergics.

The sprays segment is expected to grow at the fastest CAGR over the forecast period increasing approvals for auto-injectors and prefilled syringes. Subcutaneous injections offer numerous advantages and ease of use, such as self-administration, reliability, precise dosing in prefilled syringes, compliance, compactness, and enhanced patient comfort, all of which contribute to the growing demand in the market.

End Market Insights

Based on the end market, the hospitals segment dominated the pharmaceuticals market, with a revenue share of 42.7% in 2023. This growth is attributed to the presence of well-equipped healthcare facilities, a rising geriatric population, and a surge in prevalent chronic conditions.  pivotal role as centralized care providers enables efficient procurement and distribution of pharmaceuticals, solidifying hospitals as a prominent end market in the industry.

Clinics are estimated to expand at the fastest CAGR from 2024 to 2030. This segment plays a crucial role in preventive care, early diagnosis, and managing common illnesses. For instance, clinics are often the first point of contact for individuals seeking medical attention, allowing for timely intervention & reducing the burden on hospitals. Moreover, certain key players prioritize the health of their employees and make high efforts to provide necessary healthcare facilities to them.

Key France Pharmaceuticals Company Insights

Leading companies in the France pharmaceutical market and drug development industries are always focusing on innovative therapeutic drugs to enhance patient health outcomes, along with R&D activities by implementing some growth strategies. For instance, in October 2023, Sanofi came up with a strategic initiative to increase its R&D capabilities. The focus of the strategy was to escalate transformative medicine, vaccine production, skilled resource deployment, and increase pipeline potential. The company announced the separation of the consumer health business to support R& investments.

Recent Developments

• In January 2024, France-based SANOFI agreed to acquire a U.S.-based drug development project of INBRX-101 from the parent company Inhibrx Inc. for around 2.2 billion dollars to escalate the business of rare diseases. This acquisition will help to enhance the company’s revenues from the anti-inflammatory drugs and boost the R&D domain of the company.

• In November 2023, AbbVie announced the agreement with ImmunoGen and its significant cancer therapy namely ELAHERE. This acquisition will accelerate AbbVie’s commercial and clinical expansion in the tumor section. In addition, ELAHERE is the first-in-class antibody-drug conjugate (ADC) which will help to supplement the ADCs division of AbbVie.

• In 2022, Sanofi and AstraZeneca together developed the world’s first vaccine against bronchiolitis. AstraZeneca spent 585 euro million for manufacturing the product while Sanofi handled the marketing of the product.

France Pharmaceuticals Market Report Scope

France Pharmaceuticals Market Market Report Segmentation

This report forecasts revenue growth at the country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the France pharmaceuticals market report based on molecule type, product, type, disease, route of administration, formulation, age group, end market, and region:

• Molecule Type Outlook (Revenue, USD Billion, 2018 - 2030)

  • Biologics & Biosimilars (Large Molecules)

    • Monoclonal Antibodies

    • Vaccines

    • Cell & Gene Therapy

    • Others

  • Conventional Drugs (Small Molecules)

• Product Outlook (Revenue, USD Billion, 2018 - 2030)

  • Branded

  • Generics

• Type Outlook (Revenue, USD Billion, 2018 - 2030)

  • Prescription

  • OTC

• Disease Outlook (Revenue, USD Billion, 2018 - 2030)

  • Cardiovascular diseases

  • Cancer

  • Diabetes

  • Infectious diseases

  • Neurological disorders

  • Respiratory diseases

  • Autoimmune diseases

  • Mental health disorders

  • Gastrointestinal disorders

  • Women’s health diseases

  • Genetic and rare genetic diseases

  • Dermatological conditions

  • Obesity

  • Renal diseases

  • Liver conditions

  • Hematological disorders

  • Eye conditions

  • Infertility conditions

  • Endocrine disorders

  • Allergies

  • Others

• Route of Administration Outlook (Revenue, USD Billion, 2018 - 2030)

  • Oral

  • Topical

  • Parenteral

    • Intravenous

    • Intramuscular

  • Inhalations

  • Other

• Formulation Outlook (Revenue, USD Billion, 2018 - 2030)

  • Tablets

  • Capsules

  • Injectable

  • Sprays

  • Suspensions

  • Powders

  • Other Formulations

• Age Group Outlook (Revenue, USD Billion, 2018 - 2030)

  • Children & Adolescents

  • Adults

  • Geriatric

• End Market Outlook (Revenue, USD Billion, 2018 - 2030)

  • Hospitals

  • Clinics

  • Others